Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IQSEC3 antisense RNA 2 (IQSEC3-AS2; AC026369.3) is annotated as a long non-coding RNA (lncRNA) and is transcribed antisense to the IQSEC3 gene[3][8]. As of this writing, there is limited or no functional characterization, disease association, or documented role as a therapeutic target for IQSEC3-AS2. It is distinct from the protein-coding gene IQSEC3, which encodes a guanine nucleotide exchange factor involved in synaptic signaling[5][1]; IQSEC3-AS2 should not be confused with IQSEC3, which is a characterized protein. There are no known drugs, mechanisms of action, biomarker roles, or safety issues associated with IQSEC3-AS2.\n\nNo evidence indicates that IQSEC3-AS2 is misnamed, misspelled, or otherwise incorrect as an entry; rather, it is simply not currently recognized as a pharmacological target or marker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on IQSEC3 antisense RNA 2 (IQSEC3-AS2).